Sarda Proteins Intrinsic Value
Sarda Proteins (SRDAPRT) median intrinsic value is ₹42.67 from 2 valuation models (range ₹18–₹43), vs current price ₹88.70 — -51.9% downside (Trading Above Calculated Value), margin of safety -100.0%. Browse SRDAPRT complete financial statements for revenue, profit, balance sheet and cash flow data.
SRDAPRT Valuation Methods Summary — DCF, Graham Number & P/E
Sarda Proteins intrinsic value across 2 models vs current price ₹88.70 — upside/downside and value range per method. Also explore SRDAPRT share price charts to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹17.74 | ₹15.97 - ₹19.51 | -80.0% | Book Value/Share: ₹6.67, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹42.67 | ₹38.40 - ₹46.94 | -51.9% | Revenue/Share: ₹53.33, P/S: 0.8x |
SRDAPRT Intrinsic Value vs Market Price — All Valuation Models
Sarda Proteins fair value range ₹18–₹43 vs current market price ₹88.70 across 2 valuation models. For current market price and key ratios, visit Sarda Proteins stock price NSE.
SRDAPRT Intrinsic Value Analysis — Undervalued or Overvalued?
Sarda Proteins median intrinsic value ₹42.67, current price ₹88.70 — Trading Above Calculated Value by 51.9%, margin of safety -100.0%.
What is the intrinsic value of SRDAPRT?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Sarda Proteins (SRDAPRT) is ₹42.67 (median value). With the current market price of ₹88.70, this represents a -51.9% variance from our estimated fair value.
The valuation range spans from ₹17.74 to ₹42.67, indicating ₹17.74 - ₹42.67.
Is SRDAPRT undervalued or overvalued?
Based on our multi-method analysis, Sarda Proteins (SRDAPRT) appears to be trading above calculated value by approximately 51.9%.
SRDAPRT Financial Health — Key Ratios vs Industry Benchmarks
Sarda Proteins financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Operating Margin | -11.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 5.33x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
SRDAPRT Cash Flow Quality — Operating & Free Cash Flow
Sarda Proteins operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |